Drugs / MF59-adjuvanted quadrivalent influenza vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02587221 | Sep 2016 → Jul 2018 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MF59-adjuvanted quadrivalent influenza vaccine | “This study aimed to show the clinical efficacy of an MF59-adjuvanted quadrivalent influenza vaccine (aQIV) in adults 65 years or older compared with adults not vaccinated to...” PMID 33577767 ↗ Feb 2021 |
| Known as | aQIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02587221 ↗ |
| Modality | Vaccine | “MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)” NCT02587221 ↗ |